CBD and THC are two of the best-known cannabinoids in cannabis, but they are not interchangeable. In a UK prescription context, the difference matters for effects, side effects, legal controls, impairment risk, driving, interactions and how a prescriber thinks about suitability.
This article explains the practical difference for patients. It does not recommend a product, dose, route, ratio, strain, clinic or pharmacy. If you are prescribed, those decisions sit with the clinician. If you are not prescribed, over-the-counter CBD is not the same thing as a medical cannabis prescription.
MCPH has separate entity pages for CBD and THC. This guide connects those basics to the prescription context.
The short answer
CBD is usually discussed as the non-intoxicating cannabinoid. THC is the cannabinoid most associated with intoxication, impairment and stronger controlled-drug boundaries. Both can have side effects and both can interact with medicines.
In prescribed medical cannabis, a product may contain CBD, THC, or a defined balance of both. The balance is not a shopping preference. It is part of a clinical decision that should take account of the person’s condition, previous treatments, mental-health history, current medicines, side-effect risk, driving and daily responsibilities.
Non-prescription CBD products are a separate category. They are not the same as prescribed cannabis-based medicinal products, they should not make medicinal treatment claims, and they should be disclosed to a prescriber because they may still affect safety and interactions.
CBD in prescription context
CBD stands for cannabidiol. It does not cause the same intoxicating high associated with THC, but that does not make it risk-free or automatically suitable. NHS medical cannabis guidance notes that CBD and THC can affect how other medicines work.
In a prescription context, CBD may appear in a licensed medicine for a tightly defined condition, or in an unlicensed cannabis-based medicinal product where a specialist prescriber takes responsibility for the decision. The exact legal and regulatory route depends on the product, indication and prescribing context.
Patients sometimes arrive at a consultation already using shop-bought CBD oil, gummies, capsules or drinks. That is useful information for the clinician, but it is not the same as having tried a prescribed medicine. The prescriber still needs to know what the patient is taking, how much, how often, whether it contains other cannabinoids, and whether there have been side effects or interactions.
If you want more detail on the existing MCPH entity page, see CBD and Are there any side effects from CBD?.
THC in prescription context
THC stands for tetrahydrocannabinol. It is the cannabinoid most associated with intoxication, altered perception, sedation, anxiety, paranoia, concentration problems and impairment. Some patients may also experience symptom relief from THC-containing medicines, but that cannot be separated from the safety assessment.
In the UK, THC is a controlled substance. A THC-containing medical cannabis product can only be used lawfully where it has been prescribed and supplied through the correct medical route. Patients should not treat THC-containing products as ordinary consumer products, even if they are familiar with cannabis outside the medical system.
THC also raises driving and work-safety questions. A prescription does not mean someone is fit to drive. Patients should not drive if impaired, and they should follow their prescriber’s advice and understand the UK drug-driving law.
For the MCPH entity page, see THC.
Why ratios are clinical, not cosmetic
Medical cannabis products may be described by their CBD:THC balance or by cannabinoid content. This can make them look like a menu, but in a medical setting the balance is part of risk management.
A prescriber may think about:
- whether THC could worsen anxiety, paranoia, psychosis risk, dissociation or impairment
- whether CBD could interact with existing medicines
- whether the patient has previous adverse reactions to cannabis or cannabinoids
- whether the patient drives, works in a safety-sensitive role, or has caring responsibilities
- whether the condition being treated has evidence that supports a particular prescribed medicine or cautious trial
- whether other treatments have not worked well enough, caused problems, or been unsuitable
Patients can ask why a clinician is considering a CBD-only, THC-containing or balanced product. They can also raise concerns and preferences. The boundary is that the prescriber decides suitability, route, dose, monitoring and whether treatment should continue.
For a deeper article on this topic, see MCPH’s THC:CBD ratios explained once it is approved in this batch.
Non-prescription CBD is a different boundary
Over-the-counter CBD products in the UK sit in a different category from prescription cannabis-based medicines. Current UK consumer CBD guidance is concerned with product safety, food status and restrictions on medicinal claims. The MHRA has also made clear that products presented as treating or preventing disease can fall into medicines regulation.
For patients, the practical boundaries are:
- do not assume shop-bought CBD is equivalent to a prescribed medicine
- do not assume non-prescription CBD has been clinically assessed for your condition
- do not use CBD product marketing as medical evidence
- tell your prescriber about any CBD product you use
- check whether a product may contain other cannabinoids, including controlled cannabinoids
- avoid combining CBD with medicines or supplements without discussing interaction risk where relevant
This is not a warning that every CBD product is dangerous. It is a reminder that consumer CBD and prescribed medical cannabis answer different questions.
Interactions, side effects and impairment
CBD and THC can both affect medicine safety. Interaction questions are a normal part of specialist prescribing and pharmacist review, not a reason for patients to panic or self-diagnose risk.
Patients should disclose:
- prescribed medicines
- over-the-counter medicines
- supplements
- non-prescription CBD
- non-prescribed cannabis
- alcohol or other substance use
- previous side effects from CBD, THC or cannabis
THC-containing products need particular care around impairment, driving, machinery, work safety, childcare and caring responsibilities. CBD may be less associated with intoxication, but it can still cause side effects such as tiredness or stomach symptoms in some people and may still interact with medicines.
Mental-health history matters too. THC may be unsuitable or need extra caution where there is psychosis or schizophrenia history, bipolar or mania risk, severe anxiety, paranoia, severe depression, suicidality, substance-use concerns or previous adverse cannabis reactions.
Questions to ask a prescriber
Useful questions include:
- Why are you considering CBD, THC, or a combination in my case?
- Which parts of my medical history affect cannabinoid suitability?
- Are any of my medicines, supplements or CBD products interaction concerns?
- What side effects should I report quickly?
- How would you monitor impairment, mood, sleep, anxiety and daily functioning?
- How does THC affect driving, work safety and caring responsibilities in my case?
- What should I do if a product makes symptoms worse or causes unwanted effects?
These questions support a safer consultation. They are not a request for a specific product.
What this article is not saying
This article is not saying CBD is safe for everyone or THC is unsafe for everyone. It is not saying one cannabinoid is better. It is not recommending a ratio, a route, a dose, a strain, a clinic, a pharmacy or a product.
It is saying that CBD and THC have different practical implications in UK medical cannabis prescribing. Patients should understand the difference, disclose all cannabinoid use, and let the prescriber make the clinical decision.
Sources
- NHS: Medical cannabis
- NICE: Cannabis-based medicinal products, NG144
- NHS England: Cannabis-based products for medicinal use
- GMC: Information for doctors on cannabis-based products for medicinal use
- CQC: Cannabis-based medicinal products: what CQC expects from providers
- GOV.UK: Drug licensing factsheet: cannabis, CBD and other cannabinoids
- GOV.UK: Cannabidiol CBD guidance
- GOV.UK: MHRA statement on products containing cannabidiol
- GOV.UK: Drug driving law
